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P
eriimplant diseases are defined as
“collective term for inflammatory
reactions in the tissues surround-
ing the implants,”1 whereas periimplan-
titis was introduced as an inflammatory
process on hard and soft tissue, resulting
in pathological pocket formation and
loss of supporting bone.2
The wide range in prevalence rates
of 2.7% to 47.1%of implants1,3,4 can be
attributed to differences in the study
population, disease dentition, and implant
micro- andmacrostructures.Therefore, an
effective strategy for treating this disease
is required, otherwise a debilitating con-
dition around the affected implants will
result in loss of function and esthetics.
The development of an adherent
biofilm on the implant surface plays an
important role in the etiology of peri-
implantitis.2 As a result of this multifac-
torial, but significant role of bacteria in
the initiation and progress of infection
of periimplant diseases, elimination of
the established biofilm from the implant
surface is themain objective in the treat-
ment of periimplant mucositis and
periimplantitis.5
Several clinical protocols for the
treatment of periimplantitis have been
proposed, including mechanical
debridement, the use of antiseptics
and local or systemic antibiotics,6,7
surgical access,8–10 and regenerative11–14
or resective surgical procedures.15–18
The aim of this review is to sys-
tematically screen the literature on
surgical non–regenerative treatments
of periimplantitis, especially for radio-
logic and clinical outcomes, and to
determine predictable therapeutic
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Objectives: The aim of this review
was to systematically screen the liter-
ature on surgical non–regenerative
treatments of periimplantitis, espe-
cially for radiologic and clinical out-
comes, and to determine predictable
therapeutic options for the clinical
management of periimplantitis lesions.
Material and Methods: The
potentially relevant literature was
assessed independently by 2 reviewers
to identify clinical studies, trials, and
case series in humans describing the
surgical non–regenerative treatment
outcomes of periimplantitis with
a follow-up of at least 6 months.
MEDLINE, EMBASE, and the Co-
chrane Library were searched for
studies reporting changes in probing
depth (PD) and/or bleeding on prob-
ing (BOP) and/or radiologic mar-
ginal bone-level changes.
Results: A total of 10 publications
were included: 6 prospective random-
ized controlled trials, 1 prospective
cohort study, 2 retrospective controlled
studies, and 1 case series. Clinical
parameters can be reduced by surgical
non–regenerative treatments. Con-
cerning 3 year follow-ups, BOP and
PD values decreased more efficiently
after implantoplasty than using system-
atic administration of antibacterials.
Adjunctive local chemical irrigations
or diode laser have no long-term ef-
fects. The non–regenerative surgical
approach in combination with im-
plantoplasty also shows improved
radiographic parameters.
Conclusions: Surgical non–
regenerative treatment of peri-
implantitis can reduce the amount of
inflammation in the short-term fol-
low-up. Using implantoplasty may
result in the improvement of clinical
and radiographic parameters.
Because of limited evidence and het-
erogeneity in study design, there is
a need for randomized controlled
studies with proper design and pow-
erful sample size in the future.
(Implant Dent 2018;28:1–10)
Key Words: periimplant, dental im-
plants, periodontitis, periimplant
disease, CIST, resective, non–
augmentative, therapy, implantoplasty
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options for the clinical management of
periimplantitis lesions.
MATERIALS AND METHODS
A literature research was per-
formed in MEDLINE via the PubMed
database of the US National Library of
Medicine, OvidMEDLINE, EMBASE,
and Dentistry and Oral Sciences Source
for articles published between January
2005 and January 2018 using Medical
Subject Heading search terms “periim-
plantitis” OR “peri-implantitis” OR
“periimplant” OR “peri-implant” or
“implant” AND “failure” AND “surgi-
cal” OR “treatment” OR “therapy” OR
“non-regenerative” OR “nonregenera-
tive” OR resective OR “laser” OR
“lasers”OR “implantoplasty”OR “osteo-
plasty”OR “flap debridement” + free text
terms, and in different combinations. To
be included in the study, studies were
screened by 2 independent reviewers
and had to be
(i) written in the English language;
(ii) published in an international peer-
reviewed journal;
(iii) clinical studies or clinical trials in
humans;
(iv) prospective or retrospective studies;
(v) case series.
Case reports, letters, editorials, and
literature reviews were excluded.
According to disease definition,
periimplantitis was defined as a clear
radiographic threshold of more than
2 mm of marginal bone loss beyond
biological periimplant bone remodel-
ing, presence of bleeding on probing
(BOP), and/or suppuration.19
Finally, the matching full-text ar-
ticles were included if they fulfilled the
following criteria:
• surgical non–regenerative/resective
treatment in patients with at least 1
osseointegrated screw-shaped den-
tal implant affected by “peri-
implantitis” mentioned above
• minimal sample size of 10 implants
• minimum 6 months of follow-up
period
• description of at least 1 surgical
non–regenerative treatment method
of periimplantitis
• Report on clinical and radio-
graphic periimplant tissue
changes, including probing depth
(PD) and/or BOP as the primary
outcome measure and/or radio-
graphic bone-level (RBL) change
as the secondary outcomemeasure
The exclusion criteria were defined
as follows:
• In vitro and in vivo studies
• Studies with inclusion of patients
with severe systemic diseases and
uncontrolledmetabolic disorder or
osteoporosis
• Studies concerning ceramic or
coated implant surfaces
• Insufficient information for the
review, including unavailability
of authors
Risk of Bias Assessment
The following criteria were used
according to the randomized clinical
trial checklist of the Cochrane Center20
and the CONSORT statement.21 The
degrees of bias were categorized as fol-
lows: low risk, if all the criteria were
met; moderate risk, if 1 criterion was
missing; and high risk, if 2 or more cri-
teria were missing.
Data Extraction and Method of Analysis
All data from the eligible studies
were extracted with a data extraction
template. For data analysis, author and
year of publication, type of study,
sample size, antimicrobial adjunctive
agents, detoxification methods, as well
as PD change, BOP change, and RBL
change before treatment and after
respective healing periods including
the duration of follow-up were ex-
tracted (Table 1).
RESULTS
After initial screening of 863 poten-
tially relevant publications because of
data extraction and analysis described
above, 724 articles were excluded and
139 studies were included, aiming on
non–regenerative surgical treatments of
periimplantitis. Among these 139 stud-
ies, furthermore 129 were excluded
because of lack of information regarding
the topic, the criteria for “diagnosis peri-
implantitis” did notmatch, or the follow-
up period was too short. Finally, 10
articles were included in this review.
Six prospective randomized controlled
trials,9,10,16–18,22 1 prospective cohort
study,8 2 retrospective controlled stud-
ies,15,23 and 1 case series24 were designed
with follow-up periods of 6 months,9,24 1
year,8,10,15,22,23 and 3 years.16–18 The risk
of bias across studies was classified as
unclear risk in 5 cases (1 or more criteria
missing),8,9,17,18,22 as moderate risk in 1
case,10 and as high risk in 4 studies (2 or
more criteria missing).15,16,23,24
Clinical periimplant parameters as
PDandBOP improvedafter access apical
surgery only,8,15–17 surface decontamina-
tion with chlorhexidine (CHX), and/or
cetylpyridinium chloride (CPC)15,23 and
systemic antibiotics.8,18,22,24 One study
showed no clinical benefits using adjunc-
tive systemic azithromycin in combina-
tion with open flap debridement10;
another study stated no potential benefits
of systemic antibiotics over 3 years.18
The clinical parameters improved signif-
icantly, especially in studies performing
implantoplasty17 or use of systemic anti-
microbials.8,22 In detail, implantoplasty
(diamond/Arkansas burs + silicone pol-
ishers) as an adjunct to open flap debride-
ment with bone recontouring and apical
flap repositioning resulted in better BOP
and PD scores, but higher mean mucosal
recessions compared with the control
group (PD: 1.64 6 1.29 vs 2.3 6
1.45 mm), where persistent active signs
of periimplant inflammation recurred in
all patients after 24 months. Adjunctive
benefits, derived from the addition of re-
sective surgical treatment consisting of
apically repositioned flap, bone recon-
touring, and surface debridement with
0.12% CHX + 0.05% CPC to a placebo
solution (without CHX/CPC),15,23 tend
to show greater immediate suppression
of anaerobic bacteria on the implant sur-
face than a placebo solution, but do not
lead to superior clinical results or differ-
ences in mean marginal bone loss at 12
months of follow-up. Similarly, the
adjunctive use of 980-nm diode laser to
mechanical openflapdebridement9 failed
to reveal any significant clinical improve-
ments in mean BOP and PD scores at the
6-month follow-up (Figs. 1–5).
Stable radiographic periimplant
bone levels were observed after
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Table 1. Descriptive Analysis of Included Studies With Study and Patient/Implant Characteristics, Treatment Protocols, Clinical and Radiographic Outcomes, as Well as
Complications
Study Year Type of Study Sample Size
Follow-up
(m)
Implant
Surface
Periimplantitis
Definition
Treatment Method
Used
Decontamination
Method
Outcomes
Evaluated
Mean PD Changes
(SD)
Mean BOP
Changes Mean
(SD)
Radiographic
Marginal Bone-Level
Changes
Heitz-Mayfield
et al8
2012 Prospective
cohort
study
24 patients;
mean age 56
years
12 36 implants,
rough
BOP and/or pus
on probing +
PD $5 mm
and bone loss
$2 mm
Open flap
debridement and
implant surface
decontamination
with saline and
with adjunctive
systemic
amoxicillin and
metronidazole
Sterile saline Clinical: PD,
recessions,
BOP, and
pus;
radiographic:
MBL changes
Baseline: mean
PD $ 6 mm:
20%; 5 # PD ,
6 mm: 25%; 4 #
PD , 5 mm:
28%; , 4 mm:
7%. After 12 mo:
$ 6 mm: 0%;
5 # PD , 6 mm:
0%; 4 # PD ,
5 mm: 11%;
, 4 mm: 89%.
Statistically
significant (P ,
0.01) reduction
in mean PD.
Number of sites
with BOP:
baseline: 2.5
(1); after 12
mo: 1 (1.2)
Three implants in
3 patients had
0.6–1 mm bone
loss at 12 mo.
Statistically
signicant (P ,
0.01)
reduction in
BOP.
Three implants in
3 patients
showed bone
gain, whereas
the remaining
implants had
stable marginal
bone levels.
Papadopoulos
et al9
2015 Randomized
controlled
clinical
study
16: age 55 years.
(40–73) group
1: 8, group 2:
8
6 Not known BOP and/or pus
on probing +
PD $ 6 mm
and bone
loss $2 mm
Group 1: open flap
debridement
alone.
Group 1: use of
cotton swabs
soaked in saline
solution
Clinical: PD,
recessions,
BOP, pus,
and plaque
index;
radiographic:
MBL changes
Group 1: baseline
mean PD
5.92 mm; after 6
mo 4.44 mm;
reduction of
1.38 mm.
Group 1: baseline
93.5%; after 6
mo 31.3%;
mean
reduction
72.9%.
Group 2: open flap
debridement with
the additional
use of diode
laser
Group 2: saline
solution + diode
laser for 2 min,
532 nm;
Group 2: baseline
mean PD
5.52 mm; after 6
mo 4.31 mm;
reduction of
1.19 mm.
Group 2: baseline
81.2%; after 6
mo 23.8%;
mean
reduction
66.7%
(P , 0.05)
No statistically
significant
difference
between the 2
groups.
No statistically
significant
difference
between
groups
de Waal
et al15
2013 Retrospective
clinical
study
30: group 1: 15,
age 61.5
years; group
2: 15, age
59.4 years
12 79 implants,
rough
BOP and/or pus
on probing +
PD $5 mm
and bone loss
$2 mm
Resective surgery
with bone
recontouring and
surface
decontamination.
Test: 0.12%
CHX+0.05%
cetylpyridinium
chloride (CPC);
control: no
CHX/CPC
Clinical: BOP,
PD, and pus;
radiographic:
MBL loss
after 1 y and
comparison
between the
groups
Mean PD $ 5 mm:
group 1:
baseline 88.2
(18.4)%; after
12 mo 733.9
(39)%.
Group 1: baseline
87.1 (27)%;
after 12 mo
25.8 (8)%.
Group 1: baseline
4.3 (2.1) mm;
after 12 mo 5
(2.5) mm.
Group 2:
baseline 3.61
(1.9) mm; after
12 mo 3.9
(2) mm.
Group 1: 0.12%
CHX + 0.05%
CPC.
Group 2: baseline
75.2 (26.1)%;
after 12 mo 17.1
(24)%
Group 2: baseline
81.3 (39)%;
after 12 mo
15.8 (6)%.
(continued on next page)
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Table 1. (Continued)
Study Year Type of Study Sample Size
Follow-up
(m)
Implant
Surface
Periimplantitis
Definition
Treatment Method
Used
Decontamination
Method
Outcomes
Evaluated
Mean PD Changes
(SD)
Mean BOP
Changes Mean
(SD)
Radiographic
Marginal Bone-Level
Changes
Group 2: placebo. Mean PD $ 6 mm:
Group 1: baseline
54.5 (33.7)%;
after 12 mo 17.7
(34.3)%.
Group 2: baseline
46.9 (33.7)%;
after 12 mo 17.2
(19.2)%.
Romeo et al17 2005 Randomized
clinical
study
17: group 1: 10;
group 2: 7
36 35 implants,
rough
Pus or BOP, PD.
4 mm, no
mobility, and
radiographic
horizontal bone
loss
Group 1 (test):
resective surgery
and modification
of surface
topography
(implantoplasty)
Metronidazole +
tetracycline
hydrochloride
(3 min)
Clinical: survival
rate, PD, mBI,
and mucosal
recession
index
Group 1: baseline
5.79 (1.69) mm;
after 36 mo 3.21
(0.56) mm
Group 1: baseline
2.83 (0.47);
after 36 mo
0.61 (0.67)
Group 2: resective
surgery only
(control group)
Group 2: baseline
6.52 (1.62) mm;
after 24 mo 5.5
(1.47) mm.
Group 2: baseline
2.86 (0.35);
after 24 mo
2.33 (0.75)
Romeo et al16 2007 Randomized
clinical
study
19: group 1: 10;
group 2: 9
36 38 implants,
rough
Pus or BOP, PD
. 4 mm, no
mobility,
radiographic
horizontal
bone loss
Group 1 (test):
resective surgery
and
implantoplasty.
Group 2
(control):
resective surgery
alone.
Metronidazole +
tetracycline
hydrochloride
(3 min)
Radiographic:
marginal
bone loss
Group 1: baseline
mesially 3.82
(1.52) mm,
distally 3.94
(1.64) mm; after
3 y mesially
3.81 (3.94) mm,
distally 1.72
(1.79) mm.
Group 2: baseline
mesially 3.45
(1.93) mm,
distally 3.49
(1.8) mm; after
3 y mesially
5.35 (1.99) mm,
distally 5.42
(1.91) mm
Significantly higher
(P , 0.05)
mean MBL was
recorded in
group 2 than in
group 1.
de Waal
et al23
2015 Retrospective
clinical
study
44: group 1: 22,
age 60.5
years; group
2: 22, age
58.6 years
12 108
implants,
rough
BOP and/or pus
on probing +
PD $ 5 mm
and bone loss
$2 mm
Resective surgery
with bone
recontouring and
surface
decontamination.
Test: 2.0% CHX;
control: 0.12%
CHX+0.05% CPC
Clinical: BOP,
PD, and pus;
radiographic:
MBL loss
after 1 y and
comparison
between the
groups
Mean PD $ 5 mm:
Group 1: baseline
57.5 (26.6)%;
after 12 mo 7.3
(12.6)%.
Group 1: baseline
82.1 (23.9)%;
after 12 mo
42.7 (34.2)%.
Group 1: baseline
4 (1.5) mm;
after 12 mo 4.3
(1.7) mm.
(continued on next page)
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Table 1. (Continued)
Study Year Type of Study Sample Size
Follow-up
(m)
Implant
Surface
Periimplantitis
Definition
Treatment Method
Used
Decontamination
Method
Outcomes
Evaluated
Mean PD Changes
(SD)
Mean BOP
Changes Mean
(SD)
Radiographic
Marginal Bone-Level
Changes
Group 1: 0.2% CHX. Group 2: baseline
60.2 (28.3)%;
after 12 mo 5.3
(12.5)%.
Group 2: baseline
74.2 (27.8)%;
after 12 mo
37.0 (35.3)%.
Group 2: baseline
4.1 (1.6) mm;
after 12 mo 4.1
(1.7) mm.
Group 2: 0.12%
CHX + 0.05%
CPC.
Mean PD $
6 mm: Group
1: baseline
29.1 (31.6)%;
after 12 mo
2.1 (7)%.
No significant
difference
between the
groups (P ¼
0.6)
Radiologic bone
loss was not
significantly
different
between the
groups (P ¼
0.8)
Group 2: baseline
34.4 (31.8)%;
after 12 mo 1.4
(5.8)%.
No significant
difference
between the
groups
(P ¼ 0.6)
Carcuac
et al22
2016 Randomized
controlled
clinical
study
100/179; group
1: 27/47,
nonmodified
surface (N) 3,
modified (M)
44; group 2:
25/46, N 12,
M 34; group
3: 24/49, N
15, M 34;
group 4: 24/
37, N 13, M
24
12 Different
surfaces
included
PD $ 6 mm +
BOP and/or
pus bone loss
.3 mm
Bone recountouring
+: groups 1 and
2 systemic
antibiotics
(amoxicillin 2*750
mg, 10 d,
commenced 3
d before surgery)
0.2% CHX for 2 min
in group 1 and 3;
saline groups in
group 2 and 4
Clinical: PD,
BOP, and
pus;
radiographic:
MBL
changes
Group 1:
−3.03 mm;
group 2:
−3.44 mm;
group 3:
−2.16 mm;
group 4:
−1.69 mm;
reduction in
PPD occurred
in all treatment
groups but was
significantly
larger in group
2 than in
groups 3
and 4.
Group 1: 18%;
group 2: 16%;
group 3: 20%;
group 4: 18%;
no significant
differences
between
treatment
groups
Group 1: 0.18 mm;
group 2:
0.51 mm;
group 3:
−0.69 mm;
group 4:
−0.96 mm.
Bone gain was
observed in
implants in
patients of
groups 1
and 2,
whereas
additional
bone loss
occurred in
the other 2
groups
(continued on next page)
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Table 1. (Continued)
Study Year Type of Study Sample Size
Follow-up
(m)
Implant
Surface
Periimplantitis
Definition
Treatment Method
Used
Decontamination
Method
Outcomes
Evaluated
Mean PD Changes
(SD)
Mean BOP
Changes Mean
(SD)
Radiographic
Marginal Bone-Level
Changes
. P , 0.05
groups 1 and 2
vs groups 3
and 4
Carcuac
et al18
2017 Randomized
controlled
clinical
study
67/121 group 1:
68 implants;
group 2:
53 implants;
group 3:
90 implants;
group 4:
31 implants
36 Different
surfaces
included
PD $ 6 mm +
BOP and/or
pus bone loss
.3 mm
Bone recountouring
+: Groups 1 and
2 systemic
antibiotics
(amoxicillin 2*750
mg, 10 d,
commenced 3 d
before surgery)
0.2% CHX for 2 min
in group 1 and 3;
saline groups in
group 2 and 4
Clinical: PD,
BOP, and
pus;
radiographic:
MBL
changes
Group 1: −3 mm;
group 2:
−2.38 mm;
group 3:
−2.67 mm;
group 4:
−2.9 mm; PD
reduction was
more
pronounced at
the non–
modified sur-
face implants
and that
adjunctive use
of systemic an-
tibiotics
improved the
outcome at im-
plants with
modified surfa-
ces
BoP/SoP+ was
lower for
implants with
non–modified
surfaces,
ranging from
27% to 44%,
when com-
pared with
modified sur-
face implants
(70%) Sys-
temic anti-
biotics had no
effect in terms
of BoP/SoP.
Group 1:
−0.32 mm;
group 2:
0.51 mm;
group 3:
0.28 mm;
group 4:
−0.65 mm.
Hallström
et al10
2017 Randomized
controlled
clinical
study
Control: 16/16;
test: 15/15
12 Different
surfaces
included,
rough
BOP and/or pus
on probing +
PD $ 5 mm
and bone loss
$2 mm
Test group: open
flap
debridement,
cleaning with
sterile curettes
and saline-
soaked cotton
gauzes,
Zithromax
250 mg 3 2 on
the day of
surgery, and
250 mg 3 1 per
day during
4 additional d;
control group:
Open flap
debridement,
cleaning with
sterile curettes
and saline-
soaked cotton
gauzes
saline-soaked cotton
gauzes
Clinical: PD,
BOP, and
pus;
radiographic:
MBL
changes;
microbial
samples
Successful clinical
outcome: PPD
# 5 mm, no
suppuration, no
BOP at the
implant sites,
and bone loss
#0.5 mm.
Statistical analysis
failed to
demonstrate
differences in
BOP scores.
Mean gain of
alveolar bone at
implants
assessed from
radiographs
was also
significant
(mean diff:
0.4 mm, SE
mean diff:
0.2 mm, 95%
CI: 0.0, 0.8, P ,
0.05)
Based on the both
treatment
groups, 11/31
individuals
(35.5%)
presented with
a successful
treatment
outcome.
(continued on next page)
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systemic application of antibiot-
ics8,10,22 or local use of chemical com-
pounds.15,23 In studies with significant
improvement of clinical periimplant pa-
rameters after implantoplasty, RBLs
and marginal bone loss were signifi-
cantly lower after 3 years of follow-
up,16 with interproximal bone loss at
control sites up to 1.45 to 1.54 mm.
A total number of 35 implants were
removed after non–augmentative sur-
gery and progressive recurrence of
periimplant inflammation.15–18,22 Be-
cause of implant neck fracture, 1
implant was removed.23
Four studies reported on the smok-
ing status of the patients, ranging from
25%8 to 59.1%23 Despite 2 studies8,10
reporting no negative effect of smoking
on treatment outcome, smoking was
influencing treatment success when
adjusted for baseline and follow-up.15,23
DISCUSSION
Surgical techniques are used de-
pending on multiple factors including
patient general health condition, oral
hygiene, type of bony defects, implant
surface, postoperative maintenance pro-
gram, and other factors that cannot be
completely assumed in a systematic lit-
erature review. The non–augmentative
treatment concept is indicated for su-
pracrestal bone defects (horizontal bone
loss)with exposed threads in esthetically
non–demanding areas based on patient
needs and satisfaction and involves
reduction or elimination of pathological
periimplant pockets, the apical posi-
tioning of a mucosal flap, or recontour-
ing bonewith or without implant surface
modification, called implantoplasty. In
case of modifications of implant surfa-
ces, the rough design should be removed
and polished. However, a concern of
remaining titanium particles should be
addressed.
Even in cases of periimplant mu-
cositis, it can be advisable to perform an
access flap for proper mechanical and
chemical decontamination (ie, addi-
tional removal of cement remnants) of
the implant surface.
The resolution of infection can be
achieved by a proper method of implant
surface decontamination. Clinical studies
comparing different decontamination
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methods or placebo failed to reveal
significant differences between different,
locally applied decontaminationmethods
on clinical treatment outcomes.15,23 Nev-
ertheless, a combined mechanical and
chemical removal of biofilm is further
recommended.5 Furthermore, adjunctive
systemic antibiotics had no impact on the
treatment’s success for implants with
a machined surface, and a positive effect
was observed for the treatment success of
implants with rough surfaces only in the
first year.22 Local antibiotic delivery in
addition to mechanical debridement and
irrigation with an antimicrobial agent
may be an effective option for treating
periimplantitis lesions.6,7 Moreover, the
development of bacterial resistance
seems to be an unlikely even in the event
of repeated applications.25
Resective periimplantitis therapy
combined with implantoplasty leads to
superior clinical and radiographic treat-
ment outcomes compared with resec-
tive treatment alone. In particular,
implantoplasty, which can be per-
formed with diamond or carbide burs
and metal polishing instruments with
irrigation, positively influenced implant
survival rates (100% test, 87.5%control
group), significantly reduced periim-
plant pocket depths, and reduced bleed-
ing scores.17 Implantoplasty was
associated with stabile interproximal
bone levels at the 3-year follow-up,
although significantly radiographic
bone loss at control sites was de-
tected.16 However, the gingival reces-
sion index was significantly higher
when implant surface modification
was performed.17 Therefore, this type
of surgical technique can be of benefit
primarily in the non–esthetic areas, and
alternative treatments should be devel-
oped for the esthetic zone.5
The resective therapy outcomes
were influenced by the experience of
the surgical team, the amount of periim-
plant bone loss, maximum probing
pocket depth at baseline, as well as
a patient’s smoking habits, and the pres-
ence of plaque during the follow-up.23
Analysis of studies and achieved
reliability of treatments that revealed
similarities in treatment approaches
between protocols included (1) pre-
treatment phase, (2) cause-related ther-
apy, and (3) maintenance phase. Oral
hygiene instructions and its importance
must be stressed to patients before and
after the treatment.26 Nonsurgical sub-
gingival mechanical debridement in
conjunction with local antibacterials,
such as chlorhexidine digluconate or
locally delivered antibiotics, is effective
in reducing soft-tissue inflammation7,27
and should be the first step in successful
Fig. 4. A surgical, non–augmentative treat-
ment of periimplantitis was performed,
including an open flap debridement, after im-
plantoplasty of infected and exposed implant
surfaces, chemical surface decontamination
and disinfection of the implants, and minimally
invasive osteoplasty concerning only small in-
trabony defects. After minimal-invasive access
flap, implant surfaces were treated with dia-
mond burs and finally polished with greenies
and supergreenies. Internal gingivectomy was
completed before minimal-invasive osteo-
plasty and apical reposition flap with periosteal
sutures.
Fig. 3. Baseline radiographs showing hori-
zontal bone loss with a supracrestal defect
height of 3 to 5 mm. In addition, vertical de-
fects could be detected around the implants
35 and 36 with a depth of 3 mm. The com-
bination of the clinical and radiographic di-
agnostics stated a clear indication for
surgical, non–augmentative treatment of the
periimplantitis.
Fig. 5. After a 3-year-follow-up, no signs of
inflammation, proper oral hygiene, and suffi-
cient keratinized mucosa were present.
Implant recessions of 2 to 3 mm resulted
from the non–augmentative surgical peri-
implantitis. Supportive periodontal treatment
took place every 3 months after the diagnosis
of periimplantitis.
Fig. 1. Clinical situation (baseline) of a 53-
year-old patient suffering from periimplantitis
in the left lower jaw, with massive soft-tissue
swelling, redness, ulceration, and BOP. Im-
plants were inserted 14 years ago, but there
was no adherence to a supportive peri-
odontal treatment for the past 6 years. Nev-
ertheless, his oral hygiene was acceptable
and implants were placed too buccally, but
surrounded by adequate keratinized mucosa.
Fig. 2. Eight weeks after nonsurgical treat-
ment with mechanical (plastic ultrasonic
device) and chemical debridement (hydrogen
peroxide 3% and chlorhexidine digluconate
solution 0.2%), as well as adjunctive local
antibiotics (tetracycline derivate), the clinical
situation showed furthermore signs of mas-
sive inflammation. For a proper surgical
treatment, including implantoplasty, it was
absolutely necessary to remove the supra-
structure, especially in the lower jaw.
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treatment.26 The supportive treatment
phase is mandatory for the success of
periimplantitis treatment.26 In a 5-year
follow-up observational study, healthy
periimplant tissue conditions in patients
with high oral hygiene standard (main-
tenance every 6months) could bemain-
tained for most patients after resective
periimplant surgery.28 Further disease
progression occurred only in 10% of
the treated implants, revealing that risk
factors including the presence of resid-
ual pockets after surgery, smoking,
poor oral hygiene, untreated periodon-
tal disease, and diabetes may modify
both the initial and long-term outcome
of the treatment.26
All studies included implants with
both cemented or screw-retained supra-
structures. Hence, some surgeries were
performed with suprastructures in place
and some after removal of the supra-
structures. All clinical assessments
were performed with suprastructures
in place. The suprastructure probably
might affect quality of implant decon-
tamination and modification and flap
design and possibly themeasurement of
clinical parameters. If possible, it is
strongly recommended to remove the
suprastructure during surgical interven-
tion and might be adapted for better
cleansing ability.
Limitations of the revised studies
are relatively small sample sizes and
short follow-up periods. Furthermore,
there were inconsistencies in method-
ology with various treatment modali-
ties, limited control groups, different
implant systems, and follow-up results
from the same research groups. Unclear
or high risk of bias of included studies
may have an effect on the conclu-
sions.20 The evidence of the review is
limited due to significant variations
observed in the included studies. There-
fore, there is a substantial need for ran-
domized controlled studies with a proper
design and powerful sample size to pro-
vide strong and comparable evidence of
benefits of non–augmentative procedures
for treating periimplantitis.
CONCLUSIONS
The present systematic review
showed that surgical non–regenerative
modalities treating periimplantitis can
reduce the amount of inflammation in
the short-term follow-up, but seem less
effective in the long-term perspective.
Using implantoplasty in surgical non–
regenerative treatment leads to a signif-
icant decrease in BOP and PD and may
result in improvement of clinical and
radiographic parameters up to 3 years
after surgery compared with mechani-
cal debridement alone. Application of
systemic antibiotics, chemical com-
pounds, or diode laser did not result in
significant clinical or radiographic
long-term improvements.
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